USANA Health Sciences (NYSE:USNA) PT Lowered to $35.00

USANA Health Sciences (NYSE:USNA) had its price target lowered by investment analysts at DA Davidson from $38.00 to $35.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. DA Davidson’s price objective indicates a potential downside of 7.43% from the stock’s previous close. DA Davidson also issued estimates for USANA Health Sciences’ Q4 2024 earnings at $0.49 EPS, FY2024 earnings at $2.45 EPS and FY2025 earnings at $2.23 EPS.

Separately, StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 24th.

USANA Health Sciences Trading Up 3.4 %

Shares of USNA opened at $37.81 on Wednesday. USANA Health Sciences has a 12 month low of $34.15 and a 12 month high of $54.81. The firm’s 50 day moving average is $37.96 and its 200-day moving average is $42.51. The stock has a market capitalization of $720.28 million, a PE ratio of 13.36, a P/E/G ratio of 1.15 and a beta of 0.89.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million for the quarter, compared to analysts’ expectations of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. During the same period last year, the firm posted $0.59 earnings per share. Equities research analysts predict that USANA Health Sciences will post 2.5 earnings per share for the current fiscal year.

Insider Transactions at USANA Health Sciences

In other news, Director John Turman Fleming sold 1,000 shares of USANA Health Sciences stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the transaction, the director now owns 2,503 shares in the company, valued at approximately $111,208.29. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Paul A. Jones sold 6,266 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Turman Fleming sold 1,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the transaction, the director now owns 2,503 shares in the company, valued at approximately $111,208.29. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 7,940 shares of company stock worth $311,670. Company insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

Several institutional investors have recently made changes to their positions in USNA. DGS Capital Management LLC raised its holdings in shares of USANA Health Sciences by 61.8% during the first quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock valued at $352,000 after purchasing an additional 2,773 shares during the period. BNP Paribas Financial Markets increased its position in shares of USANA Health Sciences by 18.1% during the first quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company’s stock worth $1,883,000 after acquiring an additional 5,952 shares in the last quarter. Pzena Investment Management LLC increased its position in shares of USANA Health Sciences by 3.1% during the first quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock worth $38,089,000 after acquiring an additional 23,729 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of USANA Health Sciences by 22.7% during the first quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock worth $409,000 after acquiring an additional 1,560 shares in the last quarter. Finally, BOKF NA increased its position in shares of USANA Health Sciences by 274.5% during the first quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after acquiring an additional 2,031 shares in the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.